Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia

Recognify Life Sciences, Inc., an atai Life Sciences platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment Associated with Schizophrenia (CIAS), today announced it has initiated a Phase 2a study for its lead compound RL-007, after receiving IND clearance from the Food and Drug Administration to commence clinical trials in the United States in this indication.